A2A Receptor Antagonists: Potential Adjuvant Therapies For Levodopa Optimisation

A2A receptor antagonists: potential adjuvant therapies for levodopa optimisation

Parkinson's Europe

A2A antagonist improves dopaminergic function and reduces neuroinflammation in a rodent model of PD

Adjunctive MAO-B or COMT inhibitors to optimize levodopa treatment in PD

Levodopa dose adjustment versus adjunctive therapy in Parkinson’s disease

Extending the efficacy of levodopa in patients with Parkinson’s disease

Medical vocabulary: What does Receptor, Adenosine A2A mean

botcaster bot (B Bot)

Medication Options for Parkinson’s Symptoms: A to Z Review

The Victory Summit: Medications and Parkinson's

Davis Phinney Foundation for Parkinson's

Other Benefits of Nourianz

Public Health Channel

BIPARK-I and II: opicapone and levodopa in PD with motor fluctuations

Kyowa Kirin's Nourianz (istradefylline): A FDA approved new drug for Parkinson’s Disease treatment

Doses Of Videos

What’s in the Parkinson’s Pipeline? Medical Therapies

Parkinson's Foundation

New Diagnosis Workshop Series (2023): PD Management and Treatment

ParkinsonSocietyBC

Nutritional effects on A2A adenosine receptors and their role in mediating diet-induced inflammation

Texas A&M Nutrition and Food Science

Phase II study of NE3107 in levodopa/carbidopa-treated patients with Parkinson's disease

Levodopa and the pharmacological revolution in Parkinson's disease

Parkinson's disease: what’s to come in 2022?

Dr James Beck Discusses FDA Approval of DUOPA for Treatment of Advanced Parkinson’s

Parkinson's Foundation

A Dive into the Different Parkinson's Drug Classes